 Eric Rush
Concepts (230)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypophosphatasia | 11 | 2024 | 11 | 4.420 |
Why?
| | Osteogenesis Imperfecta | 7 | 2023 | 8 | 2.000 |
Why?
| | Alkaline Phosphatase | 9 | 2023 | 18 | 1.850 |
Why?
| | Humans | 46 | 2024 | 6929 | 1.450 |
Why?
| | Bone Density Conservation Agents | 5 | 2023 | 10 | 1.420 |
Why?
| | Intellectual Disability | 6 | 2024 | 34 | 1.380 |
Why?
| | Craniofacial Abnormalities | 4 | 2020 | 11 | 1.290 |
Why?
| | Recombinant Fusion Proteins | 5 | 2021 | 14 | 1.290 |
Why?
| | Immunoglobulin G | 5 | 2021 | 34 | 1.290 |
Why?
| | Bone Density | 5 | 2023 | 44 | 1.270 |
Why?
| | Male | 29 | 2024 | 3367 | 1.260 |
Why?
| | Female | 23 | 2024 | 3534 | 1.230 |
Why?
| | Genetic Diseases, X-Linked | 2 | 2021 | 4 | 1.170 |
Why?
| | Developmental Disabilities | 7 | 2024 | 42 | 1.130 |
Why?
| | Diphosphonates | 4 | 2023 | 13 | 1.110 |
Why?
| | Neurodevelopmental Disorders | 5 | 2024 | 23 | 1.020 |
Why?
| | Adolescent | 15 | 2023 | 2183 | 1.010 |
Why?
| | Child | 21 | 2024 | 3348 | 0.970 |
Why?
| | Mutation | 11 | 2023 | 213 | 0.940 |
Why?
| | Osteoporosis | 3 | 2019 | 25 | 0.890 |
Why?
| | Infant | 15 | 2023 | 1449 | 0.870 |
Why?
| | Phenotype | 13 | 2023 | 256 | 0.820 |
Why?
| | Child, Preschool | 14 | 2023 | 1562 | 0.820 |
Why?
| | Hypophosphatemia | 1 | 2021 | 5 | 0.810 |
Why?
| | Familial Hypophosphatemic Rickets | 1 | 2021 | 9 | 0.800 |
Why?
| | Zellweger Syndrome | 3 | 2015 | 3 | 0.780 |
Why?
| | Abnormalities, Multiple | 2 | 2013 | 36 | 0.780 |
Why?
| | Adult | 14 | 2024 | 1199 | 0.760 |
Why?
| | Cost of Illness | 1 | 2019 | 19 | 0.690 |
Why?
| | Congenital Disorders of Glycosylation | 1 | 2017 | 1 | 0.610 |
Why?
| | Phosphotransferases (Alcohol Group Acceptor) | 1 | 2017 | 2 | 0.610 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2017 | 9 | 0.610 |
Why?
| | Aorta | 1 | 2016 | 9 | 0.570 |
Why?
| | Bone Diseases, Metabolic | 2 | 2017 | 8 | 0.560 |
Why?
| | Hearing Loss | 2 | 2013 | 4 | 0.540 |
Why?
| | Cardiovascular Diseases | 1 | 2016 | 49 | 0.540 |
Why?
| | Heart Ventricles | 1 | 2016 | 55 | 0.540 |
Why?
| | PPAR gamma | 1 | 2015 | 1 | 0.540 |
Why?
| | Anemia, Aplastic | 1 | 2015 | 1 | 0.540 |
Why?
| | Trisomy | 1 | 2015 | 2 | 0.540 |
Why?
| | Echocardiography | 1 | 2016 | 93 | 0.540 |
Why?
| | Sex Chromosome Disorders of Sex Development | 1 | 2015 | 4 | 0.540 |
Why?
| | Opportunistic Infections | 1 | 2015 | 7 | 0.540 |
Why?
| | Chromosome Deletion | 2 | 2016 | 21 | 0.480 |
Why?
| | Chromosomes, Human, Pair 7 | 1 | 2013 | 1 | 0.450 |
Why?
| | Cleft Lip | 1 | 2013 | 8 | 0.450 |
Why?
| | Cleft Palate | 1 | 2013 | 14 | 0.450 |
Why?
| | Neurocutaneous Syndromes | 1 | 2013 | 1 | 0.440 |
Why?
| | Alopecia | 1 | 2013 | 2 | 0.440 |
Why?
| | Growth Disorders | 1 | 2013 | 25 | 0.440 |
Why?
| | Membrane Proteins | 4 | 2019 | 53 | 0.430 |
Why?
| | Treatment Outcome | 4 | 2021 | 649 | 0.430 |
Why?
| | Fractures, Bone | 3 | 2023 | 35 | 0.430 |
Why?
| | Home Care Services | 1 | 2012 | 6 | 0.410 |
Why?
| | Health Care Surveys | 1 | 2012 | 33 | 0.410 |
Why?
| | Growth | 1 | 2011 | 11 | 0.400 |
Why?
| | Severity of Illness Index | 3 | 2024 | 148 | 0.400 |
Why?
| | Ambulatory Care | 1 | 2012 | 45 | 0.390 |
Why?
| | Body Composition | 1 | 2011 | 27 | 0.390 |
Why?
| | Genomics | 2 | 2023 | 102 | 0.390 |
Why?
| | Adipose Tissue | 1 | 2011 | 27 | 0.390 |
Why?
| | Young Adult | 5 | 2023 | 641 | 0.390 |
Why?
| | Prevalence | 3 | 2023 | 150 | 0.380 |
Why?
| | Body Mass Index | 1 | 2011 | 156 | 0.370 |
Why?
| | Infant, Newborn | 5 | 2023 | 826 | 0.370 |
Why?
| | Obesity | 1 | 2011 | 124 | 0.360 |
Why?
| | Comparative Genomic Hybridization | 1 | 2010 | 9 | 0.360 |
Why?
| | Sequence Deletion | 1 | 2010 | 12 | 0.360 |
Why?
| | Bone Diseases | 2 | 2019 | 4 | 0.340 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 333 | 0.340 |
Why?
| | Europe | 2 | 2023 | 40 | 0.330 |
Why?
| | Consensus | 2 | 2024 | 33 | 0.270 |
Why?
| | Haploinsufficiency | 3 | 2021 | 11 | 0.270 |
Why?
| | Karyotyping | 2 | 2015 | 11 | 0.250 |
Why?
| | Musculoskeletal Abnormalities | 1 | 2024 | 1 | 0.240 |
Why?
| | Retrospective Studies | 5 | 2023 | 1337 | 0.240 |
Why?
| | Autistic Disorder | 2 | 2021 | 13 | 0.240 |
Why?
| | PHEX Phosphate Regulating Neutral Endopeptidase | 2 | 2021 | 2 | 0.240 |
Why?
| | Delphi Technique | 1 | 2024 | 11 | 0.240 |
Why?
| | Rare Diseases | 2 | 2022 | 42 | 0.240 |
Why?
| | Disease Progression | 1 | 2024 | 110 | 0.230 |
Why?
| | Genetic Testing | 2 | 2021 | 86 | 0.220 |
Why?
| | Forkhead Transcription Factors | 1 | 2022 | 6 | 0.220 |
Why?
| | Insurance Coverage | 1 | 2023 | 22 | 0.220 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2022 | 20 | 0.210 |
Why?
| | Surveys and Questionnaires | 2 | 2024 | 275 | 0.210 |
Why?
| | Hermanski-Pudlak Syndrome | 1 | 2021 | 1 | 0.200 |
Why?
| | Fibroblast Growth Factors | 1 | 2021 | 30 | 0.200 |
Why?
| | Enzyme Replacement Therapy | 2 | 2018 | 4 | 0.200 |
Why?
| | Calcium Channels, L-Type | 1 | 2021 | 5 | 0.200 |
Why?
| | Long QT Syndrome | 1 | 2021 | 3 | 0.200 |
Why?
| | Syndactyly | 1 | 2021 | 4 | 0.200 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2021 | 4 | 0.200 |
Why?
| | Quality of Life | 2 | 2019 | 139 | 0.200 |
Why?
| | Genes, Recessive | 1 | 2021 | 7 | 0.190 |
Why?
| | Spliceosomes | 1 | 2021 | 1 | 0.190 |
Why?
| | Mandibulofacial Dysostosis | 1 | 2021 | 3 | 0.190 |
Why?
| | Ellis-Van Creveld Syndrome | 1 | 2020 | 1 | 0.190 |
Why?
| | G-Protein-Coupled Receptor Kinase 2 | 1 | 2020 | 1 | 0.190 |
Why?
| | Hedgehog Proteins | 1 | 2020 | 7 | 0.190 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 57 | 0.190 |
Why?
| | Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2020 | 2 | 0.180 |
Why?
| | DNA Helicases | 1 | 2020 | 5 | 0.180 |
Why?
| | Brain | 2 | 2012 | 79 | 0.180 |
Why?
| | Myotonin-Protein Kinase | 1 | 2020 | 1 | 0.180 |
Why?
| | Absorptiometry, Photon | 2 | 2020 | 16 | 0.180 |
Why?
| | Practice Guidelines as Topic | 2 | 2017 | 104 | 0.180 |
Why?
| | Muscle Weakness | 1 | 2019 | 2 | 0.180 |
Why?
| | Telephone | 1 | 2019 | 6 | 0.170 |
Why?
| | Calcium-Binding Proteins | 1 | 2019 | 10 | 0.170 |
Why?
| | Genetic Predisposition to Disease | 1 | 2021 | 226 | 0.170 |
Why?
| | Mobility Limitation | 1 | 2019 | 3 | 0.170 |
Why?
| | Peroxisomes | 2 | 2015 | 2 | 0.170 |
Why?
| | Case-Control Studies | 2 | 2016 | 216 | 0.170 |
Why?
| | Pain | 1 | 2019 | 56 | 0.170 |
Why?
| | Fracture Fixation, Intramedullary | 1 | 2018 | 1 | 0.160 |
Why?
| | Tibia | 1 | 2018 | 3 | 0.160 |
Why?
| | Osteotomy | 1 | 2018 | 4 | 0.160 |
Why?
| | Femur | 1 | 2018 | 12 | 0.160 |
Why?
| | Syndrome | 2 | 2020 | 34 | 0.160 |
Why?
| | Lung | 1 | 2018 | 66 | 0.160 |
Why?
| | Testosterone | 1 | 2018 | 31 | 0.160 |
Why?
| | Osteopetrosis | 1 | 2017 | 1 | 0.150 |
Why?
| | Ichthyosis | 1 | 2017 | 2 | 0.150 |
Why?
| | Lipid Metabolism | 1 | 2017 | 7 | 0.150 |
Why?
| | Siblings | 1 | 2017 | 7 | 0.150 |
Why?
| | Outpatients | 1 | 2017 | 28 | 0.150 |
Why?
| | Drug Monitoring | 1 | 2017 | 12 | 0.150 |
Why?
| | Inpatients | 1 | 2017 | 43 | 0.150 |
Why?
| | Nebraska | 1 | 2016 | 2 | 0.140 |
Why?
| | Ventricular Remodeling | 1 | 2016 | 3 | 0.140 |
Why?
| | Dilatation, Pathologic | 1 | 2016 | 6 | 0.140 |
Why?
| | Observer Variation | 1 | 2016 | 14 | 0.140 |
Why?
| | Vascular Remodeling | 1 | 2016 | 2 | 0.140 |
Why?
| | Obsessive-Compulsive Disorder | 1 | 2016 | 6 | 0.140 |
Why?
| | Tourette Syndrome | 1 | 2016 | 6 | 0.140 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2017 | 50 | 0.140 |
Why?
| | Chromosome Disorders | 1 | 2016 | 7 | 0.140 |
Why?
| | Receptor, Parathyroid Hormone, Type 1 | 1 | 2016 | 2 | 0.140 |
Why?
| | Osteochondrodysplasias | 1 | 2016 | 3 | 0.140 |
Why?
| | Hypercalcemia | 1 | 2016 | 10 | 0.140 |
Why?
| | Ventricular Function, Left | 1 | 2016 | 30 | 0.140 |
Why?
| | Parathyroid Hormone | 1 | 2016 | 24 | 0.140 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 102 | 0.140 |
Why?
| | Peroxisomal Disorders | 1 | 2015 | 1 | 0.140 |
Why?
| | Lumbosacral Region | 1 | 2015 | 2 | 0.140 |
Why?
| | Femur Neck | 1 | 2015 | 6 | 0.140 |
Why?
| | Osteogenesis | 1 | 2015 | 6 | 0.140 |
Why?
| | Chromosomes, Human, X | 1 | 2015 | 6 | 0.130 |
Why?
| | Sex Chromosome Aberrations | 1 | 2015 | 6 | 0.130 |
Why?
| | Bone Marrow Transplantation | 1 | 2015 | 17 | 0.130 |
Why?
| | Reproducibility of Results | 1 | 2016 | 198 | 0.130 |
Why?
| | Tracheoesophageal Fistula | 1 | 2016 | 27 | 0.130 |
Why?
| | Graft Survival | 1 | 2015 | 33 | 0.130 |
Why?
| | Vitamin D | 1 | 2015 | 22 | 0.130 |
Why?
| | Cohort Studies | 2 | 2019 | 281 | 0.130 |
Why?
| | Pedigree | 3 | 2022 | 61 | 0.130 |
Why?
| | Prospective Studies | 1 | 2016 | 547 | 0.120 |
Why?
| | Middle Aged | 3 | 2023 | 645 | 0.120 |
Why?
| | Factor VII Deficiency | 1 | 2014 | 3 | 0.120 |
Why?
| | Muscle Hypotonia | 2 | 2024 | 7 | 0.110 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2013 | 13 | 0.110 |
Why?
| | Liver Transplantation | 1 | 2014 | 47 | 0.110 |
Why?
| | Corneal Diseases | 1 | 2013 | 1 | 0.110 |
Why?
| | Hypesthesia | 1 | 2013 | 1 | 0.110 |
Why?
| | Rhombencephalon | 1 | 2013 | 4 | 0.110 |
Why?
| | Cerebellum | 1 | 2013 | 13 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 2 | 2012 | 122 | 0.110 |
Why?
| | Infusions, Intravenous | 1 | 2012 | 27 | 0.100 |
Why?
| | Cost-Benefit Analysis | 1 | 2012 | 27 | 0.100 |
Why?
| | Patient Satisfaction | 1 | 2012 | 44 | 0.100 |
Why?
| | Program Evaluation | 1 | 2012 | 45 | 0.100 |
Why?
| | New Zealand | 1 | 2011 | 4 | 0.100 |
Why?
| | Frameshift Mutation | 2 | 2022 | 5 | 0.100 |
Why?
| | Anthropometry | 1 | 2011 | 16 | 0.100 |
Why?
| | Genotype | 2 | 2023 | 408 | 0.100 |
Why?
| | Overweight | 1 | 2011 | 50 | 0.100 |
Why?
| | Age Factors | 1 | 2011 | 211 | 0.090 |
Why?
| | Glucose Transporter Type 4 | 1 | 2010 | 1 | 0.090 |
Why?
| | Connexins | 1 | 2010 | 3 | 0.090 |
Why?
| | Animals | 2 | 2024 | 741 | 0.090 |
Why?
| | Exons | 2 | 2024 | 35 | 0.090 |
Why?
| | Aged | 2 | 2019 | 411 | 0.080 |
Why?
| | Prognosis | 2 | 2019 | 216 | 0.080 |
Why?
| | Mammals | 1 | 2024 | 4 | 0.060 |
Why?
| | Reactive Oxygen Species | 1 | 2024 | 9 | 0.060 |
Why?
| | Neuroblastoma | 1 | 2024 | 14 | 0.060 |
Why?
| | Delayed Diagnosis | 1 | 2023 | 4 | 0.060 |
Why?
| | Health Personnel | 1 | 2024 | 24 | 0.060 |
Why?
| | Teriparatide | 1 | 2023 | 1 | 0.060 |
Why?
| | Fracture Fixation | 1 | 2023 | 2 | 0.060 |
Why?
| | Artificial Intelligence | 1 | 2023 | 14 | 0.060 |
Why?
| | Vomiting | 1 | 2023 | 23 | 0.060 |
Why?
| | Genome | 1 | 2022 | 33 | 0.050 |
Why?
| | Sequence Analysis, DNA | 1 | 2022 | 116 | 0.050 |
Why?
| | United States | 1 | 2024 | 670 | 0.050 |
Why?
| | Craniofacial Dysostosis | 1 | 2021 | 1 | 0.050 |
Why?
| | Limb Deformities, Congenital | 1 | 2021 | 2 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2022 | 100 | 0.050 |
Why?
| | Wnt Signaling Pathway | 1 | 2020 | 4 | 0.050 |
Why?
| | Catalytic Domain | 1 | 2020 | 4 | 0.050 |
Why?
| | Amino Acid Sequence | 1 | 2020 | 36 | 0.040 |
Why?
| | Heterozygote | 1 | 2020 | 27 | 0.040 |
Why?
| | Mutation, Missense | 1 | 2020 | 28 | 0.040 |
Why?
| | Ligands | 1 | 2019 | 5 | 0.040 |
Why?
| | North America | 1 | 2019 | 43 | 0.040 |
Why?
| | Vital Capacity | 1 | 2018 | 6 | 0.040 |
Why?
| | Spirometry | 1 | 2018 | 6 | 0.040 |
Why?
| | Forced Expiratory Volume | 1 | 2018 | 10 | 0.040 |
Why?
| | Respiratory Function Tests | 1 | 2018 | 16 | 0.040 |
Why?
| | Internal Fixators | 1 | 2018 | 4 | 0.040 |
Why?
| | Radioimmunoassay | 1 | 2018 | 3 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2018 | 10 | 0.040 |
Why?
| | Mass Spectrometry | 1 | 2018 | 18 | 0.040 |
Why?
| | Reoperation | 1 | 2018 | 64 | 0.040 |
Why?
| | Calcitriol | 1 | 2017 | 6 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 47 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2017 | 45 | 0.040 |
Why?
| | Incidence | 1 | 2017 | 134 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2017 | 130 | 0.040 |
Why?
| | Chromosomes, Human, Pair 13 | 1 | 2016 | 3 | 0.040 |
Why?
| | Chromosomes, Human, Pair 18 | 1 | 2016 | 3 | 0.040 |
Why?
| | Retinal Dystrophies | 1 | 2015 | 1 | 0.030 |
Why?
| | Hearing Loss, Sensorineural | 1 | 2015 | 3 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2016 | 32 | 0.030 |
Why?
| | Precision Medicine | 1 | 2015 | 43 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2016 | 329 | 0.030 |
Why?
| | Risk Factors | 1 | 2016 | 490 | 0.030 |
Why?
| | Intracranial Hemorrhages | 1 | 2014 | 7 | 0.030 |
Why?
| | Indians, North American | 1 | 2012 | 9 | 0.030 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|